Pfizer Inc. (NYSE: PFE) has seen a decline in its stock price by -0.17 in relation to its previous close of 29.27. However, the company has experienced a 0.21% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-10-20 that Pfizer’s deep valuation and large dividend yield make it an attractive investment, despite potential distractions from activist investors. The focus should remain on existing cost realignment plans and pipeline investments to ensure positive financial returns for shareholders. The stock only trades at 10x forward EPS targets.
Is It Worth Investing in Pfizer Inc. (NYSE: PFE) Right Now?
PFE has 36-month beta value of 0.65. Analysts have mixed views on the stock, with 11 analysts rating it as a “buy,” 1 as “overweight,” 9 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PFE is 5.66B, and currently, short sellers hold a 1.19% ratio of that float. The average trading volume of PFE on October 21, 2024 was 31.49M shares.
PFE’s Market Performance
The stock of Pfizer Inc. (PFE) has seen a 0.21% increase in the past week, with a -1.48% drop in the past month, and a -1.28% fall in the past quarter. The volatility ratio for the week is 1.36%, and the volatility levels for the past 30 days are at 1.75% for PFE. The simple moving average for the past 20 days is 0.29% for PFE’s stock, with a 3.57% simple moving average for the past 200 days.
Analysts’ Opinion of PFE
Many brokerage firms have already submitted their reports for PFE stocks, with Bernstein repeating the rating for PFE by listing it as a “Mkt Perform.” The predicted price for PFE in the upcoming period, according to Bernstein is $32 based on the research report published on October 17, 2024 of the current year 2024.
PFE Trading at 0.57% from the 50-Day Moving Average
After a stumble in the market that brought PFE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.59% of loss for the given period.
Volatility was left at 1.75%, however, over the last 30 days, the volatility rate increased by 1.36%, as shares sank -0.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.60% upper at present.
During the last 5 trading sessions, PFE rose by +0.21%, which changed the moving average for the period of 200-days by -1.72% in comparison to the 20-day moving average, which settled at $29.13. In addition, Pfizer Inc. saw 1.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PFE starting from DAMICO JENNIFER B., who sale 5,154 shares at the price of $28.66 back on Aug 13 ’24. After this action, DAMICO JENNIFER B. now owns 8,582 shares of Pfizer Inc., valued at $147,714 using the latest closing price.
Gottlieb Scott, the Director of Pfizer Inc., purchase 3,000 shares at $26.47 during a trade that took place back on Dec 15 ’23, which means that Gottlieb Scott is holding 9,000 shares at $79,401 based on the most recent closing price.
Stock Fundamentals for PFE
Current profitability levels for the company are sitting at:
- 0.03 for the present operating margin
- 0.49 for the gross margin
The net margin for Pfizer Inc. stands at -0.05. The total capital return value is set at 0.01. Equity return is now at value -2.78, with -1.19 for asset returns.
Based on Pfizer Inc. (PFE), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at 0.12. The debt to equity ratio resting at 0.79. The interest coverage ratio of the stock is 0.54.
Currently, EBITDA for the company is 10.53 billion with net debt to EBITDA at 8.26. When we switch over and look at the enterprise to sales, we see a ratio of 4.21. The receivables turnover for the company is 4.88for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
To put it simply, Pfizer Inc. (PFE) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
